The lawsuit, filed by Levi & Korsinsky, LLP, covers the period between May 13, 2025, and February 19, 2026. Plaintiffs contend that leadership intentionally withheld results from the trial's screening round, using the pretext of protecting trial integrity to mask adverse trendlines. These internal figures allegedly indicated that the three-year screening duration was insufficient to show a statistically significant reduction in Stage III and IV cancers.
Investors Face August Deadline in Grail Securities Class Action
Grail, Inc. investors have until August 4, 2026, to apply for lead plaintiff status in a securities class action lawsuit. The litigation centers on allegations that the company concealed internal data suggesting its NHS-Galleri trial would fail to meet its primary clinical endpoint, leading to a 50.55% stock price collapse.
During the class period, management touted high specificity rates of 99.5% and a cancer signal origin accuracy of 88%, while simultaneously deflecting analyst requests for precise predictive value data. Joseph E. Levi, lead attorney for the firm, argues that this selective disclosure prevented shareholders from assessing the true risks to the company’s primary clinical goals. Following the trial's failure, Grail shares plummeted by $51.32, prompting the current legal challenge to recover losses for those who purchased stock at prices allegedly inflated by the company's incomplete transparency.
Comments (0)
No comments yet. Be the first!